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ABSTRACT
Objectives: The objective of the present systematic review was to test the hypothesis of no difference in facial swelling, pain 
and trismus after surgical removal of mandibular third molar with different dosages of corticosteroids and administration 
routes.
Material and Methods: A MEDLINE (PubMed), Embase database and Cochrane Library search in combination with a hand-
search of relevant journals was conducted by including randomized controlled trials published in English until 1st December 
2017.
Results: Seven studies fulfilled the inclusion criteria. Considerable variation in the included studies prevented meta-analysis 
from being performed. Preoperative submucosal injection of corticosteroids significantly diminishes facial swelling, pain 
and trismus compared with placebo. However, different dosages of corticosteroid and administration routes reveal contrary 
results indicating that administration of a higher dosage of corticosteroids do not necessarily cause a further decrease in facial 
swelling, pain and trismus.
Conclusions: Consequently, the optimal dosage of corticosteroids and administration route for diminishing postsurgical 
morbidity and improve quality of life after surgical removal of mandibular third molar is presently unknown. Therefore, 
further well-designed randomized clinical trials including a standardised protocol, patient-reported outcome measures and 
three-dimensional analysis of facial swelling is needed.
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INTRODUCTION
Removal of impacted mandibular third molar (M3) 
is one of the most common performed surgical 
interventions in dental practice and is often associated 
with facial swelling, pain and trismus [1]. These 
postoperative sequelae arise as a result of the natural 
inflammatory response and often influence the 
patients’ ability to perform their daily activities and 
compromise the immediate quality of life [2-5]. Age, 
gender, medical status, smoking, poor oral hygiene, 
anatomy, time length of surgical procedure and 
experience of the surgeon has been associated with an 
increased risk of postoperative sequelae after surgical 
removal of M3 [6-8]. Various treatment modalities 
have been attempted to prevent or diminish the initial 
inflammatory response associated with surgical 
removal of M3 including pharmacological therapies, 
cryotherapy, local compression and surgical drains 
[9-15]. 
Corticosteroids are a class of steroid hormones that 
are produced in the adrenal cortex of vertebrates [16]. 
The synthetic analogues of these hormones are the 
most commonly preferred pharmaceutical agents for 
decreasing the severity of the natural inflammatory 
response after surgical removal of M3. Corticosteroids 
suppress each stage of the initial inflammatory 
response comprising a decrease in the permeability 
and capillary dilatation by inhibiting the production 
of vasoactive substances and reducing the amount of 
cytokines [17,18]. Moreover, prostaglandin formation 
is also inhibited by corticosteroids, thereby facilitating 
some analgesic effects [19,20]. The potential side 
effects of corticosteroids depend on the intensity and 
duration of the treatment. Side effects to a single dose 
of corticosteroids have never been described in oral 
surgery [21-23]. Moreover, postoperative infection 
due to the immunosuppressive effect of corticosteroid 
has not been observed in oral surgery [24].
Corticosteroids can be administrated systemically or 
by local injection in the surgical area. Corticosteroids 
are classified according to their potency, duration of 
action, relative mineral corticosteroid and 
plasma half-life (Table 1). Dexamethasone, 
methylprednisolone and betamethasone are the most 
commonly administered types of corticosteroids 
for diminishing the initial inflammatory response 
after surgical removal of impacted M3. As 
documented in systematic reviews, various dosages 
of corticosteroids and durations of treatment as 
well as different routes of administration have 
been used revealing dissimilar effects on facial 
swelling, pain and trismus [21-23,25,26]. Numerous 
systematic reviews have concluded that short-term 
administration of corticosteroids significantly reduces 
the degree of facial swelling, pain and trismus after 
surgical removal of impacted M3 [22,23,25,26]. 
Moreover, parenteral and preoperative prescription 
of corticosteroids seems to be superior compared 
to other routes and time of administration [25]. 
However, many of the included studies disclosed 
huge heterogeneity, high risk of bias and various 
confounding variables. Moreover, randomized 
controlled trials (RCT) comparing different 
dosages of corticosteroids with similar routes of 
administration or similar dosage of corticosteroids 
with different routes of administration are scarce 
[23,25]. A recent published systematic review and 
meta-analysis concluded that submucosal injection 
of dexamethasone significantly diminished facial 
swelling and pain after surgical removal of impacted 
M3, whereas no statistically significant difference in 
trismus was revealed between dexamethasone and 
placebo [26]. Moreover, an improved outcome for a 
specific dosage of dexamethasone was not identified 
in the meta-analysis [26]. These results are in 
accordance with a newly published systematic review 
and meta-analysis assessing systematic corticosteroids 
in orthognathic surgery disclosing that systemic 
corticosteroids is not supported by strong scientific 
evidence [27].
Consequently, there seems to be no clear practice 
consensus regarding the most effective regime for 
administration of corticosteroids to diminish facial 
swelling, pain and trismus after surgical removal of 
Table 1. Duration of action and anti-inflammatory potency of corticosteroids
Corticosteroid Duration ofaction
Anti-inflammatory
potency
Equivalent
dose
Cortisol Short (< 12 hours) 1 20 mg
Prednisone
Intermediate
(12 - 36 hours)
4 5 mg
Prednisolone 4 5 mg
Methylprednisolone 5 4 mg
Dexamethasone
Long (> 36 hours)
25 0.75 mg
Bethamethasone 25 0.75 mg
http://www.ejomr.org/JOMR/archives/2018/2/e1/v9n2e1ht.htm J Oral Maxillofac Res 2018 (Apr-Jun) | vol. 9 | No 2 | e1 | p.3
(page number not for citation purposes)
JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH                                                                  Larsen et al.
impacted M3. Therefore, the objective of the present 
systematic review was to test the hypothesis of 
no difference in facial swelling, pain or trismus 
after surgical removal of impacted M3 with 
different dosages of corticosteroids and routes of 
administration.
MATERIAL AND METHODS 
Protocol and registration
The present systematic review was conducted in 
accordance with the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) 
statement for reporting systematic reviews [28]. The 
methods of the analysis, inclusion and exclusion 
criteria were specified in advance and documented 
in a protocol. The protocol was registered in 
PROSPERO, an international prospective register 
of systematic reviews. It can be accessed at: 
https://www.crd.york.ac.uk/PROSPERO/, with the 
registration number: CRD42017071955.
Types of publications
The review included studies on humans. Letters, 
editorials, PhD theses, letters to the editor, case 
reports, abstracts, technical reports, conference 
proceedings, animal or in vitro studies and literature 
review papers were excluded. 
Types of studies
The review included all RCT comparing facial 
swelling, pain and trismus after surgical removal 
of mandibular M3 with different dosages of 
corticosteroids or routes of administration. 
Types of outcome measures
The outcome measures are outlined in Table 2. 
Information sources
The search strategy incorporated examinations of 
electronic databases, supplemented by a thorough 
 
hand-search page by page of relevant journals (Figure 
1). The manual search also included the bibliographies 
of all articles selected for full-text screening as well as 
previously published reviews relevant for the present 
systematic review. Two of the reviewers (MKL, TSJ) 
performed the search. If disagreements occurred, 
another reviewer was consulted (TK).
Search strategy 
A Medline (Pubmed), Embase and Cochrane Library 
search was conducted. Human studies published 
in English until 1st December 2017 were included. 
The search strategy was performed in collaboration 
with a medical librarian utilized a combination of 
Medical subject heading (MeSH) and free text terms. 
The search strategy is outlined in Appendix 1 - 3. 
Selection of studies
The PRISMA flow diagram presents an overview 
of the selection process (Figure 1). The titles of the 
identified reports were initially screened. The abstract 
was assessed when the title indicated that the study 
fulfilled the inclusion criteria. Full-text analysis was 
carried out when the abstract was unavailable or when 
the abstract indicated that the inclusion criteria were 
fulfilled. The references of the identified papers were 
cross-checked for unidentified articles. The study 
selection was performed by two reviewers (MKL, 
TSJ). If disagreements occurred, another reviewer was 
consulted (TK).
Study eligibility
The inclusion criteria were developed using the 
PICOS guidelines (Table 3).
Inclusion criteria
Human RCT assessing the treatment outcome 
following surgical removal of M3 with the use 
of different dosages or administration routes of 
corticosteroids were included by addressing the 
previously described outcome measures. Moreover, at 
least 20 patients should be included and the surgeon 
Table 2. Outcome measures
Swelling, evaluated by angles or distances between different reference points of the face
Pain, evaluated by visual analog scale or consumption of painkillers
Trismus, evaluated by interincisal distance
Patient-reported outcome measures and assessment of quality of life, evaluated by questionnaires and visual analog scale
Complications
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Figure 1. PRISMA flow diagram demonstrating the results of the systematic literature search.
Table 3. PICOS guidelines
Patient and population (P) All adult healthy patients (> 15 years) with indications for surgical removal of mandibular third molars.
Intervention (I) Surgical removal of mandibular third molars in conjunction with administration of corticosteroids.
Comparator or control 
group (C)
Surgical removal of mandibular third molars with different dosage or administration routes of 
corticosteroids.
Outcomes (O) Facial swelling, pain, trismus, complications, patient-reported outcome measures, quality of life measures.
Study design (S) Randomized controlled trials in humans with the aim of comparing the postoperative outcome following surgical removal of mandibular third molars with different doses or administration routes of corticosteroids.
Focused question Are there any differences in the postoperative outcome following surgical removal of mandibular third molars with different doses or administration routes of corticosteroids?
as well as assessors should be blinded. Inclusion and 
exclusion criteria and the used surgical technique 
should be clearly specified. In addition, the anatomical 
location and the surgical difficulty of the impacted 
M3 should be specified according to a well-known 
classification system. Moreover, the methods used for 
assessment of facial swelling, pain and trismus should 
be useful for statistical analysis. 
Exclusion criteria
The following exclusion criteria were applied: letters 
to the editor, case reports, cohort-studies, case-series, 
retrospective studies, technical reports, conference 
proceedings, animal or in vitro studies and review 
papers. Moreover, studies with insufficient description 
of patient selection, surgical procedure, dosage of 
corticosteroids and administration route as well as 
studies including medically compromised patients 
were excluded. Moreover, non-blinded RCT and 
studies comparing the effects of corticosteroids 
with other pharmacological therapies or combining 
corticosteroids with other medications were also 
excluded. 
 
Data extraction
Data were extracted by two of the reviewers (MKL, 
TSJ) according to a data-collection form ensuring 
systematic recording of the outcome measures. In 
addition, relevant characteristics of the study were 
recorded. The corresponding author was contacted 
 
 
 
Titles identified through 
database searching 
n = 800 
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Titles after duplicates removed 
n = 526 
Abstracts screened 
n = 526 
Abstracts excluded 
n = 507 
Full-text articles 
assessed for eligibility 
n = 19 
Full-text articles 
excluded, with reasons 
n = 12   
Studies included in 
qualitative synthesis 
n = 7 
Additional records identified 
through other sources 
n = 1 
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by e-mail in the absence of important information or 
ambiguities. 
Data items 
The following items were collected from the included 
studies and arranged in the following fields: authors 
and year of publication, total number of patients, 
mean age in year, sex distribution, groups, number 
of patients in the groups, administration time, route 
of administration, type of corticosteroid, dosage of 
corticosteroid, dosage of corticosteroid converted to 
dosage in dexamethasone, swelling, pain and trismus. 
Assessment of methodological quality 
The quality assessment of the included studies 
was undertaken by one reviewer (MKL) as part 
of the data extraction process. The Cochrane 
Collaboration’s tool for assessing risk of bias was 
used as a methodological quality rating system and 
the classification of the risk of bias potential for 
each study was based on seven criteria as outlined in 
Table 4 [29]. 
Statistical analysis
Meta-analyses were to be conducted only if there 
were studies of similar comparison, reporting identical 
outcome measures. However, the included studies 
revealed considerable variations in study design, i.e. 
administration routes, dosages, observation period 
and postoperative measurements. Therefore, meta-
analysis was not applicable. However, the amount 
of facial swelling and trismus among the included 
studies were estimated with 95% confidence interval 
(CI) based on an estimated standard error:
SE =
SDdifference
�number of patients
 
,
where the estimated standard deviation (SD) was 
calculated by: 
SDdifference = �SDpreoperative2 + SDpostoperative2  
.
The CI were calculated by: 
lower limit = mean - 1.96 × SE
and 
upper limit = mean + 1.96 × SE.
RESULTS 
Study selection
Article review and data extraction were performed 
according to the PRISMA flow diagram (Figure 1). 
A total of 800 titles were identified and 525 abstracts 
were reviewed. Full-text analysis included 18 articles 
and seven RCT were finally included [30-35]. One 
article was included as the result of hand-searching 
[36]. 
Exclusion of studies
Twelve studies were excluded after full-text 
assessment. The reasons for excluding the studies 
were as follow: no blinding or inadequate description 
of blinding procedure [15,37-45], less than 20 
participants [46] and insufficient description of the 
surgical procedure [47].
Table 4. Included studies assessing different doses of corticosteroids
Study Year ofpublication
Patients Materials and methods Outcome measures
Number Age(years) Sex N AT AR CO DO
DO in 
DEX Swelling Pain Trismus
Lim and Ngeow 
[30] 2017 60 25 (SD 4)
11 M;
49 F
A 20
PREOP S.m.
DEX 4 mg 4 mg
*
A, B < C
*
B < A, C
*
A, B < CB 20 MET 40 mg 7.5 mg
C 20 - 0 mg 0 mg
Üstün et al. [32] 2003 20 21.9 (SD 2.6) NM
A 20
PREOP i.v. MET
1.5 mg/kg 0.5 mg/kg
- - -
B 20 3 mg/kg 1 mg/kg
Laureano Filho 
et al. [33] 2008 60 19.5
30 M;
30 F
A 30
PREOP Oral DEX
8 mg 8 mg
* - *
B 30 4 mg 4 mg
Agostinho et al. 
[34] 2014 27 21.7 (SD 6.4)
10 M;
17 F
A 27
PREOP Oral DEX
4 mg 4 mg
- - -
B 27 12 mg 12 mg
*Significant difference between groups, P < 0.05.
AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; i.v = intravenous; 
MET = methylprednisolone; N = number of interventions; PREOP = preoperatively; S.m. = submucosal; M = male; F = female.
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Study characteristics
The included studies in the present systematic 
review consisted of seven hospital-based blinded 
RCT [30-36]. Different dosages of corticosteroids 
were assessed in four studies [30,32-34]. Different 
administration routes of corticosteroids were assessed 
in one study [36], and two studies assessed different 
dosages and administration routes of corticosteroids 
[31,35]. Facial swelling, pain and trismus were 
assessed in all of the included studies, whereas 
patient-reported outcome measures and quality 
of life assessment were not reported in any of the 
included studies. The sample size varied between 
20 and 200 patients. A description of the used 
power calculation of sample size was not reported 
in any of the included studies. The method used for 
randomization was described in two studies, involving 
a random numbers table [30] or opaque envelopes 
[31]. Age distribution was described in five studies 
[31-34,36]. Gender distribution was solely described 
in three studies [30,34,36]. The surgical experience 
of the surgeon was reported in two of the included 
studies [32,33]. The duration of the operations were 
recorded in five studies [31-34,36]. Smoking habits 
among the included patients were not reported in 
any of the included studies. Different conditions and 
types of analgesics were used in the included studies. 
Regular dosages of paracetamol in the postoperative 
period were prescribed in three studies [31,33,36]. 
Dosages of 500 mg paracetamol were prescribed 
in two studies [31,36], and dosages of 750 mg 
paracetamol were prescribed in one study [33]. Pain 
was measured in the consumption of analgesics in 
three studies [30,32,34]. Paracetamol in respective 
dosages of 500 mg [32] and 750 mg [34] were used 
in two studies, and 250 mg mefanamic acid was used 
in one study [30]. The use of postoperative analgesic 
was not described in one study [35]. Different types 
and dosages of antibiotics were used in five of the 
included studies [30-32,35,36]. Amoxicillin [36] 
and phenoxymethylpenicillin [32] were prescribed 
preoperatively in two studies, whereas amoxicillin 
[30,31] and amoxicillin with clavulanic acid [35] were 
prescribed postoperatively in three studies. The use of 
antibiotics were not prescribed in two studies [33,34].
Different dosages of corticosteroids
The use of different dosages of corticosteroids after 
surgical removal of impacted M3 has been assessed in 
four studies [30,32-34] (Table 4). 
Twenty-six patients with symmetrically impacted 
M3 were random assigned to one hour preoperative 
intravenous administration of 1.5 mg/kg or 3 mg/
kg methylprednisolone in a split-mouth and double-
blinded RCT [32]. The impacted M3 were classified 
according to the Pell and Gregory system with 
equivalent degree of surgical difficulty [32]. The 
surgical procedure was separated by three weeks and 
performed by the same surgeon with patients under 
local anaesthesia. Facial swelling was evaluated using 
a tape measuring method described by Gabka and 
Matsumura [48]. Pain was determined on a daily basis 
using a questionnaire and a visual analogue scale 
(VAS). Moreover, the number of analgesics consumed 
was also registered. Trismus was determined by 
measuring maximum interincisal opening. Assessment 
of facial swelling and trismus were obtained before 
surgical intervention and two and seven days after 
surgery. A total of six patients were excluded because 
the questionnaire was not completed properly and the 
time differences between the surgeries differed more 
than five minutes [32].
Thirty patients with symmetrically impacted M3 
were random assigned to one hour preoperative oral 
consumption of 4 mg or 8 mg oral dexamethasone 
in a split-mouth and double-blinded RCT [33]. The 
impacted M3 were classified according to Winter’s 
classification with similar degree of surgical difficulty 
[49]. The surgical procedure was separated by fifteen 
days and performed by the same surgeon with patients 
under local anaesthesia. Facial swelling was evaluated 
through facial reference points’ variation. Pain was 
evaluated using a VAS. Trismus was determined by 
measuring maximum interincisal opening. Assessment 
of facial swelling and trismus were obtained before 
surgical intervention and one and two days after 
surgery. All patients participated in the follow-up 
examination [33].
Thirty-four patients with symmetrically impacted 
M3 were random assigned to one hour preoperative 
oral consumption of 4 mg or 12 mg dexamethasone 
in a split-mouth and double-blinded RCT [34]. 
The impacted M3 were classified according to the 
Pell and Gregory system with similar degree of 
surgical difficulty [50]. The surgical procedure was 
separated by fifteen days and performed by the same 
surgeon with patients under local anaesthesia. Facial 
swelling was evaluated through facial reference 
points’ variation. Pain was evaluated using a VAS. 
Moreover, the number of analgesics consumed was 
also registered. Trismus was determined by measuring 
maximum interincisal opening. Assessment of facial 
swelling and trismus were obtained before surgical 
intervention and one and two days after surgery. 
A total of seven patients were excluded due to 
pregnancy and because they did not show up at their 
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postoperative appointments or did not return after the 
first surgery [34].
Sixty-five patients with symmetrically impacted 
M3 were random assigned to preoperative 
submucosal injection of 4 mg dexamethasone, 40 
mg methylprednisolone or placebo in a double-
blinded RCT [30]. The impacted M3 were classified 
according to the Pell and Gregory system with similar 
degree of surgical difficulty [50]. The same surgeon 
performed the surgical procedure with patients under 
local anaesthesia. Facial swelling was evaluated 
through facial reference points’ variation. Pain was 
evaluated using a VAS. Moreover, the number of 
analgesics consumed was also registered. Trismus 
was determined by measuring maximum interincisal 
opening. Assessment of facial swelling and trismus 
were obtained before surgical intervention and one, 
two, five and seven days after surgery. No information 
of drop-outs or withdrawals was provided [30].
Different administration routes of corticosteroids
Different administration routes of corticosteroids after 
surgical removal of impacted M3 have been assessed 
in one study [36].
Twenty patients with symmetrically impacted M3 
were random assigned to one hour preoperative 
oral consumption of 8 mg oral dexamethasone 
or intramuscular injection (deltoid muscle) of 8 
mg dexamethasone in a split-mouth and double-
blinded RCT [36]. The impacted M3 were classified 
according to their horizontal angulation with similar 
degree of surgical difficulty but no classification 
system was specified. The surgical procedure was 
separated by one month and performed by the same 
surgeon with patients under local anaesthesia. Facial 
swelling was evaluated by different facial reference 
points/landmarks. Pain was evaluated using VAS. 
Moreover, the number of analgesics consumed was 
also registered. Trismus was determined by measuring 
maximum interincisal opening. Assessment of facial 
swelling and trismus were obtained before surgical 
intervention and one, three and seven days after 
surgery. No information of drop-outs or withdrawals 
was provided [36].
Different dosages and administration routes of 
corticosteroids
Different dosages and administration routes of 
corticosteroids after surgical removal of impacted M3 
have been assessed in two studies [31,35].
Forty-three patients were allocated to endo-alveolar 
administration of 4 mg or 10 mg dexamethasone or 
submucosal injection 10 mg dexamethasone in a split-
mouth and double-blinded RCT [35]. The impacted 
M3 were classified according to the Pell and Gregory 
system with similar degree of surgical difficulty [50]. 
The surgical procedure was separated by at least 
four weeks and performed by the same surgeon with 
patients under local anaesthesia. Facial swelling 
was evaluated by different facial reference points’/
landmarks. Pain was evaluated using VAS. Trismus 
was determined by measuring maximum interincisal 
opening. Assessment of facial swelling and trismus 
were obtained before surgical intervention and two 
and seven days after surgery. No information of drop-
outs or withdrawals was provided [35]. 
Two hundred patients with symmetrically impacted 
M3 were random assigned to one hour preoperative 
oral consumption of 8 mg dexamethasone or 
intravenous administration of 4 mg dexamethasone 
in a split-mouth and double-blinded RCT [31]. The 
impacted M3 were classified according to the Pell 
and Gregory system with similar degree of surgical 
difficulty according to Pederson’s Index [50]. The 
surgical procedure was separated by two weeks and 
performed with patients under local anaesthesia. 
No information was provided about the number of 
surgeons. Facial swelling was evaluated using facial 
reference points’ variation according to Neupert et al. 
[51]. Pain was evaluated using VAS. Moreover, the 
number of analgesics consumed was also registered. 
Trismus was determined by measuring maximum 
interincisal opening. Assessment of facial swelling 
and trismus were obtained before surgical intervention 
and one, two and seven days after surgery. A total of 
five patients did not participate in the study follow-up 
period for unreported reason [31].
The main results are described below and summarized 
in Tables 4 - 6.
Quality assessment
The quality of the included studies is summarized in 
Table 7. A low risk of bias was found in two studies 
[30,35]. Unclear risk of bias was found in five studies, 
since the randomization method was not described 
[31-34,36]. 
Outcome measures
The result of each outcome measure is presented 
first and then a short summary is finally provided. 
All the reported numerical values are presented as 
mean values. Patient-related outcome measures 
were not reported in any of the included studies and 
therefore not described below or in Tables 4 - 6. 
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Table 6. Included studies assessing different doses and administration routes of corticosteroids
Study Year ofpublication
Patients Materials and methods Outcome measures
Number Age(years) Sex N AT AR CO DO
DO in 
DEX Swelling Pain Trismus
Chaudhary et al. [31] 2015 200 20.8 NM
A 100
PREOP
i.v.
DEX
4 mg 4 mg
- - -
B 100 Oral 8 mg 8 mg
Graziani et al. [35] 2006 43 24 (SD 4) 13 M; 30 F
A 15
POSTOP
E.a.
DEX
4 mg 4 mg
*
A, B,
C < D
*
A <
B, C, D
*
A, B <
C, D
B 14 E.a. 10 mg 10 mg
C 14 S.m. 4 mg 4 mg
D 43 - 0 mg 0 mg
*Significant difference between groups, P < 0.05.
AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; E.a. = endo-alveolar; 
i.v. = intravenous; N = number of interventions; NM = not mentioned; POSTOP = postoperatively; PREOP = preoperatively; 
S.m. = submucosal; M = male; F = female.
Table 7. Quality assessment of included studies using Cochrane Collaboration’s tool [29]
Study Sequencegeneration
Allocation
concealment
Blinding of
participants,
personnel
Blinding of
outcome
assessors
Incomplete
outcome
data
Selective
outcome
reporting
Other
sources of
bias
Study
quality of
bias
Lim and Ngeow [30] Yes Yes Yes Yes Yes Yes Yes Low risk
Chaudhary et al. [31] Unclear Unclear Yes Yes Yes Yes Yes Unclear risk 
Üstün et al. [32] Unclear Unclear Yes Yes Yes Yes Yes Unclear risk
Laureano Filho et al. [33] Unclear Unclear Unclear Yes Yes Yes Yes Unclear risk
Agostinho et al. [34] Unclear Unclear Yes Yes Yes Yes Yes Unclear risk 
Graziani et al. [35] Yes Yes Yes Yes Yes Yes Yes Low risk
Boonsiriseth et al. [36] Unclear Unclear Yes Yes Yes Yes Yes Unclear risk 
The amount of facial swelling and trismus among the 
included studies is present in Figure 2 and 3. 
Facial swelling
Different dosages of corticosteroids disclosed 
no significant differences in facial swelling at 
any time points after preoperative intravenous 
administration of 1.5 mg/kg methylprednisolone 
compared with 3 mg/kg, submucosal injection of 
40 mg methylprednisolone compared with 4 mg 
dexamethasone and oral consumption of 4 mg 
dexamethasone compared with 12 mg, respectively 
[30,32,34]. However, a significant diminished facial 
swelling was reported after oral consumption of 
8 mg dexamethasone compared with 4 mg, one and 
two days after surgery [33]. Moreover, submucosal 
injection of 40 mg methylprednisolone or 4 mg 
dexamethasone revealed significant diminished facial 
swelling compared with placebo [30]. 
Different administration routes of corticosteroids 
disclosed no significant differences in facial swelling 
at any time points after preoperative oral consumption 
of 8 mg dexamethasone compared with intramuscular 
injection of 8 mg dexamethasone [36]. 
Different dosages and administration routes of 
corticosteroids disclosed no significant differences in 
facial swelling at any time points after intravenous 
Table 5. Included studies assessing different administration routes of corticosteroids
Study Year ofpublication
Patients Materials and methods Outcome measures
Number Age(years) Sex N AT AR CO DO
DO in 
DEX Swelling Pain Trismus
Boonsiriseth et al. [36] 2012 20 20 3 M; 17 F
A 20
POSTOP
I.m.
DEX
8 mg 8 mg
- - -
B 20 Oral 8 mg 8 mg
AR = administration route; AT = administration time; CO = corticosteroid; DEX = dexamethasone; DO = dose; I.m. = intramuscular; 
N = number of interventions; POSTOP = postoperatively; M = male; F = female.
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Figure 2. Facial swelling (mm) with different dosages of dexamethasone and administration routes.
CI = confidence interval; i.m. = intramuscular; i.v. = intravenous.
Figure 3. Trismus (mm) with different dosages of dexamethasone and administration routes.
CI = confidence interval; i.m. = intramuscular; i.v. = intravenous.
Dosages of dexamethasone and administration routes
Swelling
Trismus
Estimated mean
Estimated 95% CI
Dosages of dexamethasone and administration routes
Estimated mean
Estimated 95% CI
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administration of 4 mg dexamethasone compared 
with oral consumption of 8 mg dexamethasone 
[31]. Endo-alveolar application of 4 mg and 10 
mg dexamethasone and submucosal injection of 4 
mg dexamethasone significantly diminished facial 
swelling compared to placebo [35]. 
In summary, preoperative submucosal injection of 
corticosteroids seems to diminish facial swelling 
compared to placebo after surgical removal of 
impacted M3. However, there seems to be no 
difference in facial swelling with dissimilar dosage 
of corticosteroids or route of administration, although 
oral consumption of 8 mg dexamethasone disclosed 
significant diminished facial swelling compared 
with 4 mg during the first postoperative days [33]. 
The degree of facial swelling in the abovementioned 
studies is outlined in Figure 2. 
Pain
Different dosages of corticosteroids disclosed no 
significant differences in pain at any time points after 
preoperative intravenous administration of 1.5 mg/
kg methylprednisolone compared with 3 mg/kg, oral 
consumption of 4 mg dexamethasone compared with 
8 mg and oral consumption of 4 mg dexamethasone 
compared with 12 mg, respectively [32-34]. 
However, significant reduced pain was reported after 
submucosal injection of 40 mg methylprednisolone 
compared with 4 mg dexamethasone, one, two, 
five and seven days after surgery [30]. Moreover, 
submucosal injection of 40 mg methylprednisolone or 
4 mg dexamethasone revealed significant diminished 
pain compared with placebo [30]. 
Different administration routes of corticosteroids 
disclosed no significant differences in pain at any time 
points after preoperative oral consumption of 8 mg 
dexamethasone compared with intramuscular injection 
of 8 mg dexamethasone [36].
Different dosages and administration routes of 
corticosteroids disclosed no significant differences in 
pain at any time points after intravenous administered 
of 4 mg dexamethasone compared with oral 
consumption of 8 mg dexamethasone [31]. However, 
endo-alveolar application of 4 mg dexamethasone 
revealed significantly diminished pain compared with 
endo-alveolar application of 10 mg dexamethasone or 
submucosal injection of 4 mg dexamethasone, after 
two and seven days [35].
In summary, preoperative submucosal injection of 
corticosteroids seems to reduce postoperative pain 
compared with placebo after surgical removal of 
impacted M3. Moreover, endo-alveolar application of 
corticosteroids compared with submucosal injection 
seems to significantly diminish postsurgical pain. 
However, endo-alveolar application with a higher 
dosage of corticosteroids seems not to proportionally 
reduce pain after removal of impacted M3. 
Trismus
Different dosages of corticosteroids disclosed no 
significant differences in trismus at any time points 
after preoperative intravenous administration of 1.5 
mg/kg methylprednisolone compared to 3 mg/kg, 
submucosal injection of 40 mg methylprednisolone 
compared to 4 mg dexamethasone, and oral 
consumption of 4 mg dexamethasone compared 
to 12 mg, respectively [30,32,34]. However, a 
significant diminished trismus was reported after oral 
consumption of 8 mg dexamethasone compared to 4 
mg, one and two days after surgery [33]. Moreover, 
submucosal injection of 40 mg methylprednisolone or 
4 mg dexamethasone revealed significant diminished 
trismus compared to placebo [30].
Different administration routes of corticosteroids 
disclosed no significant differences in trismus at any 
time points after preoperative oral consumption of 
8 mg dexamethasone compared to intramuscular 
injection of 8 mg dexamethasone [36].
Different dosages and administration routes of 
corticosteroids disclosed no significant differences 
in trismus at any time points after intravenous 
administered of 4 mg dexamethasone compared to 
oral consumption of 8 mg dexamethasone [35]. Endo-
alveolar application of 4 mg dexamethasone or 10 mg 
dexamethasone reveal significantly reduced trismus at 
any time points compared to submucosal injection of 
4 mg dexamethasone [31].
In summary, preoperative submucosal injection of 
corticosteroids seems to reduce postoperative trismus 
compared with placebo after surgical removal of 
impacted M3. Moreover, endo-alveolar application 
compared with submucosal injection seems to 
decrease trismus. However, the use of a higher 
dosage of corticosteroids seems not to proportionally 
diminish trismus after removal of impacted M3. The 
degree of trismus in the abovementioned studies is 
outlined in Figure 3. 
Complications
Complications were not described in three studies 
[31,33,36] and no complications were reported in two 
studies [30,35]. One study excluded patients with 
complications and did not describe the number or 
the degree of complications [34]. Mild nausea was 
described in one patient after six days [32]. 
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In summary, complications related to preoperative 
administration of corticosteroids in conjunction with 
surgical removal of M3 seem to be negligible. 
DISCUSSION
The objective of the present systematic review was to 
test the hypothesis of no difference in facial swelling, 
pain and trismus after surgical removal of impacted 
M3 with different dosages of corticosteroid and 
routes of administration. A total of seven RCT were 
included in the present systematic review [30-36]. 
Two studies were considered low risk of bias [30,35], 
whereas five studies were considered unclear risk of 
bias [31-34,36]. Preoperative submucosal injection 
of corticosteroids significantly diminishes facial 
swelling, pain and trismus compared with placebo 
[30]. However, different dosages of corticosteroid 
and routes of administration reveal contrary results 
indicating that administration of a higher dosage 
of corticosteroids do not necessarily cause a 
proportionally decrease in facial swelling, pain and 
trismus. Moreover, the included studies revealed 
considerable heterogeneity in patient demographic, 
study design as well as evaluation methods, outcome 
measures and posed various methodological 
confounding factors, which yield serious restrictions 
to review the literature in a quantitative systematic 
manner. Hence, the conclusions drawn from the 
results of this systematic review had to be cautiously 
interpreted.
Preoperative administration of corticosteroids 
significantly diminishes facial swelling compared 
with placebo after surgical removal of M3, which has 
previously been documented in systematic reviews 
and meta-analyses [21-23,25]. These results are in 
accordance with the results of the present systematic 
review. The included studies of the present systematic 
review used two-dimensional linear [30,32,35,36] 
or angle [31,33,34] measurements for assessment 
of the postoperative facial swelling. The validity 
and reliability of quantifying volume changes 
in facial morphology by using two-dimensional 
imaging are limited and associated with significant 
ambiguity. Two-dimensional measurements lack 
appropriate facial depth and shape [52,53]. Three-
dimensional facial optical scanning technique 
improves measurement accuracy and has previously 
been used for assessment of facial swelling after 
surgical removal of impacted M3 using two different 
cooling therapy methods and low-level laser therapy, 
treatment of zygomatic fractures and in orthognathic 
surgery [54-58]. Moreover, a study with three-
dimensional photogrammetry reported that 4 mg 
dexamethasone significantly reduced facial swelling 
after surgical removal of mandibular M3 compared 
to placebo [59]. Conversely, a newly published 
RCT using three-dimensional photogrammetry 
demonstrated that 15 mg dexamethasone did not 
further reduce postoperative facial swelling compared 
with 5 mg in orthognathic surgery [24]. Hence, further 
RCT assessing the influence of corticosteroids on 
facial swelling after surgical removal of impacted M3 
should include standardized three-dimensional facial 
scanning measurements. 
Anti-inflammatory analgesic also reduces tissue 
swelling after surgical removal of M3. Dissimilar 
dosages and brands of postoperative analgesics 
were administered in the included studies, which 
presumably influence the degree of postoperative 
facial swelling [60]. Thus, further RCT assessing the 
influence of corticosteroids on postoperative facial 
swelling after surgical removal of M3 should include 
a standardized analgesics protocol.
Pain is the most common complication following 
surgical removal of M3, which may affect or impair 
the patient’s immediate quality of life and habits. The 
pain relief effect of corticosteroids is presumably due 
to the inhibitory effect on prostaglandin formation 
and diminished postsurgical facial swelling [18]. 
Preoperative administration of corticosteroids 
significantly diminishes postoperative pain compared 
with placebo after surgical removal of impacted M3, 
which has been documented in systematic reviews 
and meta-analyses [21-23,25]. These results are in 
accordance with the results of the present systematic 
review. However, the reduction in pain with the use 
of corticosteroids disclosed contradictory results 
among the included studies of the present systematic 
review [30-36]. A significant improved pain relief 
was obtained with endo-alveolar application of 
corticosteroids compared with submucosal injection, 
whereas a higher dosage of corticosteroids seemed 
not to proportionally reduce pain after surgical 
removal of impacted M3. All of the included 
studies measured pain with VAS [30-36], which 
is one of the best known and commonly preferred 
scale to measure pain [61]. Other pain assessment 
methods as verbal rating scale and full cup test 
have also been used after surgical removal of M3 
[61]. However, these assessment methods do not 
distinguish between pain tolerance or expectation 
[8]. Furthermore, three studies measured pain with 
the consumption of analgesics [30,32,34]. The type 
and dosage of analgesics varied between the studies. 
Two studies used paracetamol in different dosages 
[32,34], and one study used mefanamic acid [30]. 
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However, analgesics in regular dosages in the 
postoperative period were prescribed in three studies 
[31,33,36], and the use of postoperative analgesics 
was not described in one study [35]. Consequently, the 
reduction in pain can be related to the analgesics and 
not to the use of corticosteroids. 
Pain assessment after surgical removal of impacted 
M3 may be influenced by objective and subjective 
factors including surgical trauma, duration of surgery 
and experience of the surgeon as well as anxiety, pain 
tolerance or pain expectation [8,62]. In addition, the 
sociocultural background may also have an effect on 
the pain level [63]. Standardization of the surgical 
technique, duration of the surgical procedure and 
experienced of the surgeon was described in some of 
the included studies of the present systematic review, 
whereas none of the included studies evaluated 
patients’ anxiety, pain tolerance or expectation. Thus, 
further RCT assessing the influence of corticosteroids 
on pain after surgical removal of impacted M3 
should include a standardized postoperative protocol 
and assessment of anxiety, pain tolerance or 
expectation. 
Postsurgical trismus caused by facial swelling, 
pain, hematoma or inflammation may interfere with 
the patients’ ability to eat, speak and maintaining 
proper oral hygiene. Preoperative administration of 
corticosteroids seems to reduce trismus compared 
with placebo after surgical removal of impacted M3, 
as documented in previous published systematic 
reviews and meta-analyses [21-23,25]. However, 
a newly published meta-analysis disclosed 
no significant difference in trismus between 
corticosteroids and placebo [26]. These conflicting 
results are in accordance with the results of the 
present systematic review. Mandibular range of 
motion is commonly measured with maximum 
opening, left lateral, right lateral and protrusive 
movement. Jaw range of motion scale, TheraBite® 
(Atos Medical, Hörby, Sweden) range of motion scale 
and interincisal maximal mouth opening are different 
measurement tools to determine opening, lateral 
and protrusive mandibular range of motion [64,65]. 
TheraBite® range of motion scale is a reproducible 
and valid mouth opening measurement tool using 
a cardboard scale [65]. Linear measurements of 
interincisal maximal mouth opening before and after 
surgical removal of impacted M3 is a simple, reliable, 
reproducible and validated method for assessment 
of postsurgical trismus, which has been used in all 
of the included studies of the present systematic 
review. 
Several factors may influence postoperative sequelae 
after surgical removal of impacted M3 including 
systemic medical conditions, smoking, oral hygiene, 
physical activity, surgical trauma, duration of 
surgery and experience of the surgeon [6,7]. A newly 
published retrospective study reported that dry 
socket was the most common complication after M3 
extraction and the overall prevalence of postsurgical 
complications was 17% [66]. It has previously been 
documented in a retrospective study, that partially 
impacted teeth reveal the highest incidence of 
complications and cigarette smoking correlated 
with an increased complication rate and dry sockets 
[66]. The included studies of the present systematic 
review excluded medically compromised patients 
and smoking habits was not reported in any of the 
included studies [30-36]. However, the percentage of 
dry socket was not described in any of the included 
studies and complications were only reported in one 
study involving mild nausea [32].
Prolonged use of corticosteroids may interfere with 
the natural wound healing process and increase the 
risk of infection due to an inhibiting effect on the 
body’s inflammatory response [17,18]. However, 
increased risk of postsurgical infection related to a 
single dosage of corticosteroid has never previously 
been reported and none of the included studies of 
the present systematic review described side effects 
related to the dosage of corticosteroids or the route of 
administration.
Patient-reported outcome measures are essentially 
subjective reports of patient perceptions of their 
oral health status and its impact on their daily life 
or quality of life. The Oral Health Impact Profile 
Questionnaire (OHIP), Orofacial Esthetic Scale and 
Chewing Function Questionnaire are standardised 
methods commonly used for the assessment of 
patient-reported outcome measures. Health-related 
quality of life measures are valid and reflect the 
severity of a disease and how it affects or impairs a 
patient’s life. None of the included studies in the 
present systematic review used patient-reported 
outcome measures for assessment of the final 
treatment outcome. However, OHIP-14 and other 
questionnaires have previously been used to assess 
patient-reported outcome measures after surgical 
removal of impacted M3 revealing that administration 
of corticosteroids improve the immediate quality 
of life [39,67]. A RCT showed that submucosal 
injection and oral consumption of prednisolone 
were associated with less deterioration in quality of 
life compared to placebo after surgical removal of 
M3 [39]. Furthermore, significantly better quality 
of life was seen in patients receiving prednisolone 
into submucosa compared to oral consumption 
[39]. Consequently, further RCT assessing the 
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treatment outcome after surgical removal of M3 
with administration of corticosteroids should include 
standardized patient-reported outcome measures.
Corticosteroids can be administered before, during or 
after surgical removal of M3. None of the included 
studies in the present systematic review focused on 
the time of administration. Five studies administered 
it preoperatively [30-34], whereas two studies 
administered it postoperatively [35,36]. Preoperatively 
administered methylprednisolone has previously 
shown deterioration in postoperative swelling, pain 
and trismus compared to postoperatively administered 
corticosteroid [68]. However, postoperatively 
administered dexamethasone has provided less 
postoperative pain compared to preoperative 
administration [69]. Consequently, further RCT 
assessing the treatment outcome after surgical 
removal of M3 with different time of administration of 
corticosteroids should be performed.
To summarise, preoperative administration of 
corticosteroids significantly reduces the degree 
of facial swelling, pain and trismus after surgical 
removal of impacted M3 [22,23,25,26]. From a 
clinical and patient perspective, it would be an 
advantage to use the least dose of corticosteroids 
and submucosal injection compared to other routes 
of administration. However, the optimal dosage 
and route of administration with the highest effect 
on facial swelling, pain and trismus is presently 
unknown. Moreover, preoperative administration 
of corticosteroids in mandibular M3 surgery should 
be individualized and only prescribed in cases 
where moderate postoperative pain and swelling 
is expected.
CONCLUSIONS
The hypothesis of no difference in facial swelling, 
pain or trismus after surgical removal of impacted 
mandibular third molar with different dosages of 
corticosteroids and routes of administration could 
neither be confirmed nor rejected due to insufficient 
knowledge. Preoperative submucosal injection 
of corticosteroids significantly diminishes facial 
swelling, pain and trismus compared with placebo. 
However, different dosages of corticosteroids 
and administration routes reveal contrary results 
indicating that administration of a higher dosage 
of corticosteroids do not necessarily cause a 
proportionally decrease in facial swelling, pain 
and trismus. Consequently, the optimal dosage 
of corticosteroids and administration route for 
diminishing postsurgical morbidity and improve 
the immediate quality of life after surgical removal 
of mandibular third molar is presently unknown. 
Therefore, further well-designed randomized clinical 
trials including a standardised protocol, larger patient 
sample, patient-reported outcome measures and three-
dimensional analysis of facial swelling is needed.
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Appendix 1. Medline search until the 1st of December 2017
ID Search terms
Number of 
hits
1
(16alpha methyl 9alpha fluoroprednisolone or 9 alpha fluoro 16 alpha methyl delta corticosterone or 9alpha fluoro 11beta,17alpha,21 trihydroxy 16alpha methyl 1,4 pregnadiene 3,20 dione or 9alpha fluoro 11beta,17alpha,21 trihydroxy 16alpha methylpregna 1,4 diene 3,20 dione or 
9alpha fluoro 16alpha methyl delta corticosterone).mp.
3
2 exp Adrenal Cortex Hormones/ 377996
3
(Corticosteroid* or adrenal cortex hormone* or adrenal cortical hormone* or adrenal cortical steroid* or adrenal steroid* or adreno cortical steroid or adrenocortical or adrenocorticosteroid or cortical steroid* or cortico steroid* or corticoid* or dermocorticosteroid* or 
hydroxycorticosteroid* or glucocorticoid* or glucocorticosteroid or glucocorticoidsteroid or glucocortoid* or glycocorticoid or glycocorticosteroid).mp.
241109
4 exp dexamethasone/ 48699
5 (Dexamethasone* or fluoroprednisolone or corticosterone or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol).mp. 95961
6 exp methylprednisolone/ 18466
7
(methylprednisolone or 6 methyl delta 1 hydrocortisone or 6 methyl prednisolone or 6 methylprednisolone or 6alpha methyl delta1 hydrocortisone or adlone-40 or adlone 80 or adlone-80 or adlone 40 or depmedalone or dep medalone or depoject-80 or depoject 80 or depopred 
or esametone or firmacort or med-jec-40 or med-jec 40 or med jec 40 or medixon or mednin or medralone 80 or medrate or medrol or medrone or meprednisolone or meprelon or mesopren or methacort or methyl prednisolone or methylcotol* or methylpred or methylsterolone or 
metidrol or metrisone or metycortin or metypred or metypresol or neomedrone or nsc 19987 or nsc19987 or prednol or solomet or solu decortin or urbason).mp.
24925
8
(Dexamethasone* or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol or calonat or cebedex or cetadexon or colofoam or corsona* or cortastat or cortidex* or cortisumman or cortidron* or dacortina fuerte 
or dacortine fuerte or dalalone or danasone or de-sone la or decacortin or decadeltoson* or decaderm or decadion or decadran or decadron* decaesadril or decaject or decameth* or decasone or decaspray or decasterolone or decdan or decilone or decofluor* or dectancyl or dekacort 
or delladec or deltafluoren* or dergramin or deronil or desacort or desacortone or desalark or desameton* or desigdron or dexa cortisyl or dexa dabrosan or dexa korti or dexa scherosan or dexa scherozon or dexa-pdexa-p or dexacort* or dexacortin or dexacortin or dexadabroson 
or dexadecadrol or dexadrolor or dexagel or dexagen or dexahelvacort or dexakorti or dexalien or dexalocal or dexame or dexamecortin or dexameson* or dexametason* or dexameth* or dexamonozon or dexan* or dexapot or dexaschero* or dexason* or dexinoral or dexionil or 
dexmethsone or dexon* or dexpak or dextelan or dextrasone or dezone or dibasona or doxamethasone or esacortene or exadion* or firmalone or fluormethyl prednisolon* or fluormethylprednisolon or fluormone or fluorocort or fluorodelta or fluoromethylprednisolone or fortecortin 
or gammacorten* or grosodexon* or hexadecadiol or hexadecadrol or hexadiol or hexadrol or isnacort or isopto dex or isopto maxidex or isoptodex or isoptomaxidex or lokalison f or loverine or luxazone or marvidione or maxidex or mediamethasone or megacortin or mephameson* 
or metasolon* or methazon* ion or methazonion* or metisone lafi or mexasone or millicorten* or mk 125 or mymethasone or neoforde* or nisomethasona or novocort or nsc 34521 or nsc34521 or oftan-dexa or opticort* or oradex* or orgadrone or ozurdex or pidexon or policort or 
posurdex or predni f or prednisolone f or prodexona or prodexone or sanamethasone or santenson or santeson or sawasone or solurex or spoloven or sterasone or thilodexine or triamcimetil or vexamet or visumetazone or visumethazone).mp.
70424
9 exp prednisolone/ 49004
10
(prednisolone or pregnadien* or adelcort or antisolon or antisolone or aprednislon or aprednislone or benisolon or benisolone or berisolon or berisolone or caberdelta or capsoid or co-hydeltra or co hydeltra or codelcortone or compresolon or cortadeltona or cortadeltone or cortalone 
or cortelinter or cortisolone or cotolone or dacortin or dacrotin or decaprednil or decorti* or dehydro cortex or dehydro hydrocortison* or dehydrocortex or dehydrocortisol or dehydrocortisole or dehydrohydrocortison or dehydrohydrocortisone or delcortol or hydroxycorticosterone 
or hydrocortisone or delta cortef or delta cortril or delta ef cortelan or delta hycortol or delta hydrocortison* or delta ophticor or delta stab or delta1 dehydrocortisol* or delta1 hydrocortisone or deltacortef or deltacortenolo or deltacortil or deltacortoil or deltacortril or deltaderm or 
deltaglycortril or deltahycortol or deltahydrocortison* or deltaophticor or deltasolone or deltastab or deltidrosol or deltisilone or deltisolon* or deltolasson* or deltosona or deltosone or depo-predate or depo predate or dermosolon* or di adreson f or diadreson f or di adresone f or 
dicortol or domucortone or encortelon* or encortolon or equisolon or fernisolone* or glistelone or hefasolon or hostacortin or hydeltra or hydeltrone or hydrelta or hydrocortancyl or hydrocortidelt or hydrodeltalone or hydrodeltisone or hydroretrocortin* or inflanefran or insolone or 
keteocort or key-pred or lenisolone or leocortol or liquipred or lygal kopftinktur or mediasolone or meprisolon* or metacortalon* or metacortandralon or metacortandralone or metacortelone or meti derm or meticortelone or metiderm or morlone or mydrapred or neo delta or nisolon 
or nisolone or nsc9120 or nsc 9120 or opredsone or panafcortelone or panafcortolone or panafort or paracortol or phlogex or pre cortisyl or preconin or precortalon or precortancyl or precortisyl or pred-ject-50 or pred ject 50 or predacort or predaject or predalone or predartrina or 
predartrine or predate or predeltilone or predisole or predisyr or predne dome or prednecort or prednedome or prednelan or predni coelin or predni h tablinen or predni-helvacort or predni helvacort or prednicoelin or prednicort* or prednifor or predniment or predniretard or prednis* 
or prednivet or prednorsolon* or predonine or predorgasolon* or prelon or prelone or prenilone or prenin or prenolone or preventan or prezolon or rubycort or scherisolon or scherisolona or serilone or solondo or solone or solupren or soluprene or spiricort or spolotane or sterane or 
sterolone or supercortisol or supercortizol or taracortelone or walesolone or wysolone).mp.
169473
11 exp betamethasone/ 7021
12
(16beta methyl 9alpha fluoro delta 1 hydrocortisone or 16beta methyl 9alpha fluoroprednisolone or 9alpha fluoro 11beta or 9alpha fluoro 16beta methyl* or 9alpha fluoro 16beta methylprednisolone or adbeon or becasone or benoson or beprogel or beta methason or beta methasone 
or beta-phos* or beta phos* or betacortril or betadexamethasone or betametasone or betamethaso* or betamethazone or betnasol or betnason or betnelan or betnelan or betnesol or betnovate or betsolan or betsolon or betsopart or celestan or celestene or celeston* or Cellestoderm or 
cidoten or dermobet or diprolen or flubenisolone or methasone or nsc 39470 or nsc39470 or prednisolone or pregna 1* or rg 833 or rg833 or rinderon or sch4831 or sch 4831 or walacort).mp.
51297
13 (third Molar* or Wisdom Tooth or Wisdom Teeth).mp. 9092
14 exp Molar, Third/ 5693
15 13 or 14 10450
16 or/1-12 507742
17 15 and 16 208
18 remove duplicates from 17 204
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Appendix 2. Embase search until the 1st of December 2017
ID Search terms
Number of
hits
1
(16alpha methyl 9alpha fluoroprednisolone or 9 alpha fluoro 16 alpha methyl delta corticosterone or 9alpha fluoro 11beta,17alpha,21 trihydroxy 16alpha methyl 1,4 pregnadiene 3,20 dione or 9alpha fluoro 11beta,17alpha,21 trihydroxy 16alpha methylpregna 1,4 diene 3,20 dione 
or 9alpha fluoro 16alpha methyl delta corticosterone).mp.
5
2 exp corticosteroid/ 847846
3
(Corticosteroid* or adrenal cortex hormone* or adrenal cortical hormone* or adrenal cortical steroid* or adrenal steroid* or adreno cortical steroid or adrenocortical or adrenocorticosteroid or cortical steroid* or cortico steroid* or corticoid* or dermocorticosteroid* or hydroxycor-
ticosteroid* or glucocorticoid* or glucocorticosteroid or glucocorticoidsteroid or glucocortoid* or glycocorticoid or glycocorticosteroid).mp.
407938
4 exp dexamethasone/ 132103
5 (Dexamethasone* or fluoroprednisolone or corticosterone or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol).mp. 179319
6 exp methylprednisolone/ 81763
7
(methylprednisolone or 6 methyl delta 1 hydrocortisone or 6 methyl prednisolone or 6 methylprednisolone or 6alpha methyl delta1 hydrocortisone or adlone-40 or adlone 80 or adlone-80 or adlone 40 or depmedalone or dep medalone or depoject-80 or depoject 80 or depopred 
or esametone or firmacort or med-jec-40 or med-jec 40 or med jec 40 or medixon or mednin or medralone 80 or medrate or medrol or medrone or meprednisolone or meprelon or mesopren or methacort or methyl prednisolone or methylcotol* or methylpred or methylsterolone or 
metidrol or metrisone or metycortin or metypred or metypresol or neomedrone or nsc 19987 or nsc19987 or prednol or solomet or solu decortin or urbason).mp.
91186
8
(Dexamethasone* or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol or calonat or cebedex or cetadexon or colofoam or corsona* or cortastat or cortidex* or cortisumman or cortidron* or dacortina fuerte 
or dacortine fuerte or dalalone or danasone or de-sone la or decacortin or decadeltoson* or decaderm or decadion or decadran or decadron* decaesadril or decaject or decameth* or decasone or decaspray or decasterolone or decdan or decilone or decofluor* or dectancyl or dekacort 
or delladec or deltafluoren* or dergramin or deronil or desacort or desacortone or desalark or desameton* or desigdron or dexa cortisyl or dexa dabrosan or dexa korti or dexa scherosan or dexa scherozon or dexa-pdexa-p or dexacort* or dexacortin or dexacortin or dexadabroson 
or dexadecadrol or dexadrolor or dexagel or dexagen or dexahelvacort or dexakorti or dexalien or dexalocal or dexame or dexamecortin or dexameson* or dexametason* or dexameth* or dexamonozon or dexan* or dexapot or dexaschero* or dexason* or dexinoral or dexionil or 
dexmethsone or dexon* or dexpak or dextelan or dextrasone or dezone or dibasona or doxamethasone or esacortene or exadion* or firmalone or fluormethyl prednisolon* or fluormethylprednisolon or fluormone or fluorocort or fluorodelta or fluoromethylprednisolone or fortecortin 
or gammacorten* or grosodexon* or hexadecadiol or hexadecadrol or hexadiol or hexadrol or isnacort or isopto dex or isopto maxidex or isoptodex or isoptomaxidex or lokalison f or loverine or luxazone or marvidione or maxidex or mediamethasone or megacortin or mephameson* 
or metasolon* or methazon* ion or methazonion* or metisone lafi or mexasone or millicorten* or mk 125 or mymethasone or neoforde* or nisomethasona or novocort or nsc 34521 or nsc34521 or oftan-dexa or opticort* or oradex* or orgadrone or ozurdex or pidexon or policort 
or posurdex or predni f or prednisolone f or prodexona or prodexone or sanamethasone or santenson or santeson or sawasone or solurex or spoloven or sterasone or thilodexine or triamcimetil or vexamet or visumetazone or visumethazone).mp.
149302
9 exp prednisolone/ 112519
10
(prednisolone or pregnadien* or adelcort or antisolon or antisolone or aprednislon or aprednislone or benisolon or benisolone or berisolon or berisolone or caberdelta or capsoid or co-hydeltra or co hydeltra or codelcortone or compresolon or cortadeltona or cortadeltone or cortalone 
or cortelinter or cortisolone or cotolone or dacortin or dacrotin or decaprednil or decorti* or dehydro cortex or dehydro hydrocortison* or dehydrocortex or dehydrocortisol or dehydrocortisole or dehydrohydrocortison or dehydrohydrocortisone or delcortol or hydroxycorticosterone 
or hydrocortisone or delta cortef or delta cortril or delta ef cortelan or delta hycortol or delta hydrocortison* or delta ophticor or delta stab or delta1 dehydrocortisol* or delta1 hydrocortisone or deltacortef or deltacortenolo or deltacortil or deltacortoil or deltacortril or deltaderm or 
deltaglycortril or deltahycortol or deltahydrocortison* or deltaophticor or deltasolone or deltastab or deltidrosol or deltisilone or deltisolon* or deltolasson* or deltosona or deltosone or depo-predate or depo predate or dermosolon* or di adreson f or diadreson f or di adresone f or 
dicortol or domucortone or encortelon* or encortolon or equisolon or fernisolone* or glistelone or hefasolon or hostacortin or hydeltra or hydeltrone or hydrelta or hydrocortancyl or hydrocortidelt or hydrodeltalone or hydrodeltisone or hydroretrocortin* or inflanefran or insolone or 
keteocort or key-pred or lenisolone or leocortol or liquipred or lygal kopftinktur or mediasolone or meprisolon* or metacortalon* or metacortandralon or metacortandralone or metacortelone or meti derm or meticortelone or metiderm or morlone or mydrapred or neo delta or nisolon 
or nisolone or nsc9120 or nsc 9120 or opredsone or panafcortelone or panafcortolone or panafort or paracortol or phlogex or pre cortisyl or preconin or precortalon or precortancyl or precortisyl or pred-ject-50 or pred ject 50 or predacort or predaject or predalone or predartrina or 
predartrine or predate or predeltilone or predisole or predisyr or predne dome or prednecort or prednedome or prednelan or predni coelin or predni h tablinen or predni-helvacort or predni helvacort or prednicoelin or prednicort* or prednifor or predniment or predniretard or prednis* 
or prednivet or prednorsolon* or predonine or predorgasolon* or prelon or prelone or prenilone or prenin or prenolone or preventan or prezolon or rubycort or scherisolon or scherisolona or serilone or solondo or solone or solupren or soluprene or spiricort or spolotane or sterane 
or sterolone or supercortisol or supercortizol or taracortelone or walesolone or wysolone).mp.
395431
11 exp betamethasone/ 15970
12
(16beta methyl 9alpha fluoro delta 1 hydrocortisone or 16beta methyl 9alpha fluoroprednisolone or 9alpha fluoro 11beta or 9alpha fluoro 16beta methyl* or 9alpha fluoro 16beta methylprednisolone or adbeon or becasone or benoson or beprogel or beta methason or beta methasone 
or beta-phos* or beta phos* or betacortril or betadexamethasone or betametasone or betamethaso* or betamethazone or betnasol or betnason or betnelan or betnelan or betnesol or betnovate or betsolan or betsolon or betsopart or celestan or celestene or celeston* or Cellestoderm or 
cidoten or dermobet or diprolen or flubenisolone or methasone or nsc 39470 or nsc39470 or prednisolone or pregna 1* or rg 833 or rg833 or rinderon or sch4831 or sch 4831 or walacort).mp.
142042
13 exp molar tooth/ 29970
14 (third Molar* or Wisdom Tooth or Wisdom Teeth).mp. 8862
15 13 or 14 32793
16 or/1-12 931734
17 15 and 16 422
18 remove duplicates from 17 413
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Appendix 3. Cochrane Library search until the 1st of December 2017
ID Search terms
Number of
hits
1 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees 13030
2 MeSH descriptor: [Dexamethasone] explode all trees 2603
3 MeSH descriptor: [Methylprednisolone] explode all trees 1698
4 MeSH descriptor: [Prednisolone] explode all trees 3591
5 MeSH descriptor: [Betamethasone] explode all trees 1093
6
16alpha methyl 9alpha fluoro* or 9alpha fluoro* or Corticosteroid* or adrenal cortex hormone* or adrenal cortical hormone* or adrenal cortical steroid* or adrenal steroid* or adreno cortical steroid or adrenocortical or adrenocorticosteroid or cortical steroid* or cortico steroid* or 
corticoid* or dermocorticosteroid* or hydroxycorticosteroid* or glucocorticoid* or glucocorticosteroid or glucocorticoidsteroid or glucocortoid* or glycocorticoid or glycocorticosteroid 
22215
7 Dexamethasone* or fluoroprednisolone or corticosterone or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol 7648
8
methylprednisolone or 6 methyl delta 1 hydrocortisone or 6 methyl prednisolone or 6 methylprednisolone or 6alpha methyl delta1 hydrocortisone or adlone-40 or adlone 80 or adlone-80 or adlone 40 or depmedalone or dep medalone or depoject-80 or depoject 80 or depopred or 
esametone or firmacort or med-jec-40 or med-jec 40 or med jec 40 or medixon or mednin or medralone 80 or medrate or medrol or medrone or meprednisolone or meprelon or mesopren or methacort or methyl prednisolone or methylcotol* or methylpred or methylsterolone or 
metidrol or metrisone or metycortin or metypred or metypresol or neomedrone or nsc 19987 or nsc19987 or prednol or solomet or solu decortin or urbason 
4282
9
Dexamethasone* or adrecort or adrenocot or aeroseb dex or aflucoson* or alfalyl or anaflogistico or arcodexan* or artrosone or azium or bidexol or calonat or cebedex or cetadexon or colofoam or corsona* or cortastat or cortidex* or cortisumman or cortidron* or dacortina fuerte 
or dacortine fuerte or dalalone or danasone or de-sone la or decacortin or decadeltoson* or decaderm or decadion or decadran or decadron* decaesadril or decaject or decameth* or decasone or decaspray or decasterolone or decdan or decilone or decofluor* or dectancyl or dekacort 
or delladec or deltafluoren* or dergramin or deronil or desacort or desacortone or desalark or desameton* or desigdron or dexa cortisyl or dexa dabrosan or dexa korti or dexa scherosan or dexa scherozon or dexa-pdexa-p or dexacort* or dexacortin or dexacortin or dexadabroson 
or dexadecadrol or dexadrolor or dexagel or dexagen or dexahelvacort or dexakorti or dexalien or dexalocal or dexame or dexamecortin or dexameson* or dexametason* or dexameth* or dexamonozon or dexan* or dexapot or dexaschero* or dexason* or dexinoral or dexionil or 
dexmethsone or dexon* or dexpak or dextelan or dextrasone or dezone or dibasona or doxamethasone or esacortene or exadion* or firmalone or fluormethyl prednisolon* or fluormethylprednisolon or fluormone or fluorocort or fluorodelta or fluoromethylprednisolone or fortecortin 
or gammacorten* or grosodexon* or hexadecadiol or hexadecadrol or hexadiol or hexadrol or isnacort or isopto dex or isopto maxidex or isoptodex or isoptomaxidex or lokalison f or loverine or luxazone or marvidione or maxidex or mediamethasone or megacortin or mephameson* 
or metasolon* or methazon* ion or methazonion* or metisone lafi or mexasone or millicorten* or mk 125 or mymethasone or neoforde* or nisomethasona or novocort or nsc 34521 or nsc34521 or oftan-dexa or opticort* or oradex* or orgadrone or ozurdex or pidexon or policort or 
posurdex or predni f or prednisolone f or prodexona or prodexone or sanamethasone or santenson or santeson or sawasone or solurex or spoloven or sterasone or thilodexine or triamcimetil or vexamet or visumetazone or visumethazone 
8663
10
prednisolone or pregnadien* or adelcort or antisolon or antisolone or aprednislon or aprednislone or benisolon or benisolone or berisolon or berisolone or caberdelta or capsoid or co-hydeltra or co hydeltra or codelcortone or compresolon or cortadeltona or cortadeltone or cortalone 
or cortelinter or cortisolone or cotolone or dacortin or dacrotin or decaprednil or decorti* or dehydro cortex or dehydro hydrocortison* or dehydrocortex or dehydrocortisol or dehydrocortisole or dehydrohydrocortison or dehydrohydrocortisone or delcortol or hydroxycorticosterone 
or hydrocortisone or delta cortef or delta cortril or delta ef cortelan or delta hycortol or delta hydrocortison* or delta ophticor or delta stab or delta1 dehydrocortisol* or delta1 hydrocortisone or deltacortef or deltacortenolo or deltacortil or deltacortoil or deltacortril or deltaderm or 
deltaglycortril or deltahycortol or deltahydrocortison* or deltaophticor or deltasolone or deltastab or deltidrosol or deltisilone or deltisolon* or deltolasson* or deltosona or deltosone or depo-predate or depo predate or dermosolon* or di adreson f or diadreson f or di adresone f or 
dicortol or domucortone or encortelon* or encortolon or equisolon or fernisolone* or glistelone or hefasolon or hostacortin or hydeltra or hydeltrone or hydrelta or hydrocortancyl or hydrocortidelt or hydrodeltalone or hydrodeltisone or hydroretrocortin* or inflanefran or insolone or 
keteocort or key-pred or lenisolone or leocortol or liquipred or lygal kopftinktur or mediasolone or meprisolon* or metacortalon* or metacortandralon or metacortandralone or metacortelone or meti derm or meticortelone or metiderm or morlone or mydrapred or neo delta or nisolon 
or nisolone or nsc9120 or nsc 9120 or opredsone or panafcortelone or panafcortolone or panafort or paracortol or phlogex or pre cortisyl or preconin or precortalon or precortancyl or precortisyl or pred-ject-50 or pred ject 50 or predacort or predaject or predalone or predartrina or 
predartrine or predate or predeltilone or predisole or predisyr or predne dome or prednecort or prednedome or prednelan or predni coelin or predni h tablinen or predni-helvacort or predni helvacort or prednicoelin or prednicort* or prednifor or predniment or predniretard or prednis* 
or prednivet or prednorsolon* or predonine or predorgasolon* or prelon or prelone or prenilone or prenin or prenolone or preventan or prezolon or rubycort or scherisolon or scherisolona or serilone or solondo or solone or solupren or soluprene or spiricort or spolotane or sterane or 
sterolone or supercortisol or supercortizol or taracortelone or walesolone or wysolone 
20987
11
16beta methyl 9alpha fluoro delta 1 hydrocortisone or 16beta methyl 9alpha fluoroprednisolone or 9alpha fluoro 11beta or 9alpha fluoro 16beta methyl* or 9alpha fluoro 16beta methylprednisolone or adbeon or becasone or benoson or beprogel or beta methason or beta methasone 
or beta-phos* or beta phos* or betacortril or betadexamethasone or betametasone or betamethaso* or betamethazone or betnasol or betnason or betnelan or betnelan or betnesol or betnovate or betsolan or betsolon or betsopart or celestan or celestene or celeston* or Cellestoderm or 
cidoten or dermobet or diprolen or flubenisolone or methasone or nsc 39470 or nsc39470 or prednisolone or pregna 1* or rg 833 or rg833 or rinderon or sch4831 or sch 4831 or walacort 
9018
12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 48121
13 MeSH descriptor: [Molar, Third] explode all trees 881
14 third Molar* or Wisdom Tooth or Wisdom Teeth 2185
15 #13 or #14 2185
16 #12 and #15 183
